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Background: Infections caused by Candida albicans, a
common fungal pathogen of humans, are increasing in
incidence, necessitating development of new therapeutic
drugs. Secreted aspartic proteinase (SAP) activity is con-
sidered an important virulence factor in these infections
and might offer a suitable target for drug design. Amongst
the various SAP isozymes, the SAP2 gene product is the
major form expressed in a number of C. albicans strains.
Results: The three-dimensional structures of SAP2 com-
plexed with the tight-binding inhibitor A70450 (a syn-
thetic hexapeptide analogue) and with the general aspartic
proteinase inhibitor pepstatin A (a microbial natural prod-
uct) have been determined to 2.1 A and 3.0 A resolution,
respectively. Although the protein structure retains the
main features of a typical aspartic proteinase, it also shows
some significant differences, due mainly to several
sequence insertions and deletions (as revealed by homol-
ogy modelling), that alter the shape of the binding cleft.
There is also considerable variation in the C-terminal
structural domain.
Conclusions: The differences in side chains, and in the
conformations adopted by the two inhibitors, particularly
at their P4, P3 and P'2 positions (using standard notation
for protease-inhibitor residues), allows the A70450 struc-
ture to complement, more accurately, that of the sub-
strate-binding site of SAP2. Some differences in the
binding clefts of other SAP isoenzymes may be deduced
from the SAP2 structure.
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Introduction
Fungal infections are now widespread and pose a major
threat in hospitals, a situation made more serious by the
limitations of the anti-fungal drugs that are currently
available [1]. Candida species, and Candida albicans in par-
ticular, are the main culprits, particularly in individuals
whose immune systems have become compromised (e.g.
patients with AIDS, cancer, organ transplants and drug
addiction). Systemic infections in these patients are often
life-threatening [2]. Several factors are believed to con-
tribute to fungal pathogenicity. These include the means
for adhesion to and subsequent invasion of host tissues, as
well as the presentation of antigens [3,4]. Polymorphism,
especially in the ability to form hyphae, and phenotypic
switching in some strains, are particular properties of
C. albicans, that may also contribute to virulence [5,6].
Of the enzymes implicated in host invasion, secreted
aspartic proteinase (SAP) activity appears to have the
strongest credentials as a virulence factor [1,7], and there-
fore offers a potential target for drug intervention in
infections involving Candida species. The evidence for
SAP involvement includes its presence in tissues and flu-
ids of infected patients [7,8], correlation between extent
of SAP secretion and pathogenicity [9], and the reduc-
tion in colonising ability shown by a SAP-deficient stable
mutant of C. albicans [10]. The secretion of SAP by Can-
dida sp. enables it to use a variety of exogenous proteins
as a nitrogen source [11,12], the peptide cleavage sites
being relatively non-specific, although a preference for
hydrophobic residues immediately preceding the scissile
bond is displayed [12].
Over the past three years it has been found that C. albi-
cans possesses a family of at least eight SAP genes,
of which SAP2 is the major form expressed in a number
of strains [13,14] under laboratory conditions. SAP2
encodes a 398-residue preproprotein [15] that is pro-
cessed to a 342-residue mature enzyme, a typical aspartic
proteinase of pH optimum 3-4, displaying sensitivity to
pepstatin.A, a peptide-based inhibitor.
Members of the widespread aspartic-proteinase family are
now well characterised structurally, being mainly 13 struc-
tures organised into two domains with an Asp-Thr-Gly
(DTG)/Asp-Ser-Gly (DSG) motif in the centre of an
extended cleft [16]. The two catalytic aspartic-acid
residues are within hydrogen-bonding distance of each
other and are believed to act in concert, via an interven-
ing water molecule, to bring about the base-catalysed
cleavage of the scissile peptide bond [16]. Sequence com-
parisons of SAP2 with aspartic proteinases of known
three-dimensional (3D) structure show that SAP2 shares
22-27% identity with the fungal proteinases rhizopus-
pepsin, penicillopepsin and endothiapepsin and the
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mammalian proteinases pepsin, chymosin, renin and
cathepsin D. Homology modelling [17] has indicated
some significant structural differences, due to insertions
and deletions, from these other enzymes.
The design of SAP-specific inhibitors depends crucially
on a detailed understanding of the various SAP isozyme
structures and how they differ from host aspartic pro-
teinases. Tetragonal crystals of the SAP2 isoenzyme
suitable for X-ray diffraction analysis have been grown
in the presence of the strong inhibitor A70450 (Abbott
Laboratories) [17,18]. We report the crystal structure of
SAP2, the major secreted aspartic proteinase from C.
albicans (strain ATCC 10261), complexed with the
inhibitor A70450, to a resolution of 2.1 A. In addition,
we have solved the structure of an orthorhombic form
of the SAP2-pepstatin complex to 3.0 A resolution by
using the SAP2-A70450 structure for molecular
replacement.
Results and discussion
Structure determination
The conditions for successful crystallisation of SAP2 with
A70450 took some time to establish [17] but once they
were refined, tetragonal crystals of the complex could be
grown in one to two days. The high salt conditions used
were, however, not suitable for stable pepstatin binding as
slow cleavage of SAP2 into two fragments occurred dur-
ing crystallisation [17], the resulting crystals diffracting
weakly and anisotropically. Consequently, quite different
conditions were required for successful crystallisation of
the SAP2-pepstatin complex. Using a rotating anode gen-
erator/image plate detector system, the orthorhombic
crystals diffracted to just beyond 3.0 A resolution, com-
pared with 2.0 A for the tetragonal SAP2-A70450 crystals.
The structure of SAP2-A70450 was solved first, by a
combination of single isomorphous replacement with
anomalous scattering, and molecular replacement (MR).
Although SAP2 was a clearly identified member of the
aspartic-proteinase family, the relatively low sequence
homology with the other structurally-defined members,
the anticipated variation in loop regions (as deduced
from modelling studies [17]), and the uncertainty in ori-
entation between the two rigid-body domains [19,20],
suggested that the molecular replacement approach
might not be straightforward. This turned out to be the
case, and so it was decided early on in the analysis to
obtain data for experimental phasing by isomorphous
replacement. Interpretation of the single derivative-
phased map was greatly aided by an MR solution based
on the fungal aspartic proteinase rhizopuspepsin. The
chain tracing was, however, a relatively slow process,
largely due to weak density for several extensive loops
(particularly in the C-terminal domain), that were also
involved in intermolecular contacts. Eventually all 342
residues were placed although some uncertainty exists
for parts of the large loops, as reflected in their high
temperature factors. Assignments were in agreement
with the published sequence [15]. A difference map
revealed excellent electron density for the bound
inhibitor, and all atoms were located.
The final model gave a crystallographic R factor of
0.195 for all data between 8 A and 2.1 A resolution. An
example of the 2Fo-F c electron-density map, calculated
after the refinement was completed, is shown in
Figure 1. The model, which includes 120 water mol-
ecules, shows good stereochemistry by PROCHECK
analysis [21] and only two non-glycine residues, Asnl60
and Glnl 1, fall outside favourable regions of the
Ramachandran plot. Glnll is part of a classical y turn
[22], with ((,) angles of (69°,-48° ) and a hydrogen
bond (2.8 A) between the carbonyl oxygen of GlulO
and the amide nitrogen of Vall12.
Using the SAP2 coordinates from the final model, it was
relatively straightforward to solve the orthorhombic
SAP2-pepstatin crystal structure by molecular replace-
ment. Despite the limited data, a difference map showed
good density for the bound pepstatin molecule.
The structure of SAP2
The tetragonal and orthorhombic crystal forms reveal the
protein in almost identical conformations, despite the dif-
ferent crystal packing contacts and the different inhibitors
that are bound. The root mean square (rms) difference
between all 342 pairs of Cot atoms is 0.58 A. SAP2
possesses an overall framework that, not unexpectedly, is
Fig. 1. Part of the final 2Fo-F C electron-density map, at 2.1 A res-
olution (contoured at Ia). The map shows the interaction
between Ser35, a well-ordered water molecule, Trp39 and
Tyr84. (Figure drawn using O/OPLOT [34].)
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Fig. 2. Chain fold of SAP2 from Candida
albicans. (a),(b) A ribbon presentation
of SAP2-A70450 showing two orthogo-
nal views. Active-site aspartates are
highlighted in red; disulphides are
shown in yellow. The C-terminal struc-
tural domain is identifiable in the lower
third of (b). (c) Stereo Ca trace of
SAP2-A70450. (Figure generated using
MOLSCRIPT [47].)
typical of the monomeric aspartic-proteinase family. Such
a fold can be described as a bi-lobed, mainly 13 structure,
with a central binding cleft that can accommodate up to
nine residues of peptide substrate. Figure 2 shows two
representations of the SAP2 structure complexed to
inhibitor A70450. Each domain provides one of the
catalytic aspartate residues (Fig. 2a) that, in SAP2, are
contained in DTG and DSG motifs, respectively. This
mixed pairing is also seen in some other yeast and plant
aspartic proteinases, whereas mammalian and other fungal
enzymes have the DTG motif in both domains. The
dimeric retroviral members possess either DSG or DTG,
paired symmetrically. Within the C-terminal domain
there is a structurally distinct subdomain of about 100
residues (see Fig. 2b), that in some other aspartic
proteinases has been shown to behave as a separate rigid
body [19,20]. This domain in SAP2 comprises residues
197-215 and 223-305, and contains one disulphide bond
(between 256 and 294) which ties together a double loop
(243-255, 282-293) of random structure (Fig. 2c). These
C-terminal loops are a peripheral feature of aspartic
proteinases, forming part of the wide entrance to the
binding site. They are slightly different in the two crystal
forms and are the most highly mobile regions of the
molecule. Another loop, formed by the disulphide
47-59, is more well defined. It also flanks the binding site
but is considerably closer (Fig. 2a,c).
The pattern of secondary structure elements in SAP2, in
particular the organisation of the many 3 strands and the
two major ct-helical sections (140-146, 228-237), is simi-
lar to other known aspartic proteinases. However, some of
the turns linking these elements are different in conforma-
tion. (Major differences are outlined in the next section.)
A highly conserved feature of the aspartic proteinases is the
'flap' region (a 13 hairpin loop) which interacts centrally
with bound inhibitor/substrate, shielding the active site
from bulk solvent. In SAP2 the flap comprises residues
Lys81-Gln91, with the tyrosine at position 84 being
highly conserved, as found in other aspartic proteinases
(equivalent to Tyr75 in pepsin). There is a difference in
conformation between the two SAP2 structures around
Asp86-Gly87, due to the different inhibitors bound.
Comparison with other aspartic proteinases
The pepsin-like monomeric aspartic-proteinase family is
very well-characterised crystallographically and most of
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these proteins have also been studied as complexes
bound to a variety of transition-state analogues. Known
structures include the fungal members rhizopuspepsin
[23], endothiapepsin [24,25], penicillopepsin [26],
mucorpepsin [27] and yeast proteinase A [28], and the
mammalian representatives pepsin [29], chymosin [30],
cathepsin D [31,32] and renin [33]. (References quoted
relate to enzyme-inhibitor complexes, in most cases, and
are representative, not comprehensive.) It is of consider-
able interest to compare the SAP2 structure with both of
these groups, firstly to examine the diversity amongst
aspartic proteinases in general and the fungal group in
particular, and secondly to evaluate features exhibited in
the substrate/inhibitor-binding site of SAP2 that might
distinguish it from the binding sites of the human
homologues.
The SAP2 structure most closely resembles rhizopus-
pepsin, with an rms difference between 295 pairs of Ca
atoms of 1.54 A; the next closest are pepsin and chy-
mosin (about 1.7 A), then endothiapepsin, penicil-
lopepsin, and renin (-1.8 A). Superpositions were
carried out using the least-squares procedure in O [34].
Figure 3 shows backbone superpositions of SAP2 with
three fungal and three human enzymes, the structures of
which had been determined with a bound inhibitor
present and for which atomic coordinates were available
through the Brookhaven Protein Data Bank [35]. It is
immediately apparent that the N-terminal domains
align much better than the C-terminal domains. Figure
4 shows a sequence comparison of these proteinases,
based largely on alignment of corresponding secondary
structure elements. Seven regions of difference high-
lighted in this analysis involve additions or deletions,
some of which influence the structure of the
substrate/inhibitor-binding site.
Region I
A small deletion near the N terminus results in a fore-
shortening of the turn connecting the P-strand residues
3-9 and 15-20. The two strands are part of different
sheet structures and are virtually superimposable amongst
family members. A classical y turn in SAP2 (involving
residues 10-12) allows these two strands to maintain the
same relative positions, while at the same time it pro-
trudes less into the binding-site region (Fig. 3), which is
particularly noticeable in comparison with the other fun-
gal enzymes.
Region II
The disulphide loop enclosed by Cys47 and Cys59 is
significantly longer than in the homologous proteins
under comparison. Indeed, neither endothiapepsin nor
penicillopepsin has an equivalent disulphide, whereas
Fig. 3. Structural comparisons of aspar-
tic proteinases. (a) Stereoview of the
backbone superpositions of SAP2(white) with three fungal aspartic pro-
teinases: rhizopuspepsin (6APR;green),
endothiapepsin (4ER2;red) and penicil-
lopepsin (1APT;cyan). The roman
numerals indicate regions where SAP2
differs from the other enzymes and
these correspond to the sequences high-
lighted in Figure 4. (b) Similar compar-
isons of SAP2 (white) with three human
aspartic proteinases: pepsin (1 PSO;red),
renin (1RNE;cyan) and cathepsin D
(1LYB;green). (Figure generated using
MOLSCRIPT [471.)
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Fig. 4. Structure-based sequence alignment of SAP2 from Candida albicans 10261, rhizopuspepsin, penicillopepsin, endothiapepsin,
human pepsin, human renin, and human liver cathepsin D. Regions indicated by a bar are highlighted in the tertiary structure compar-
isons of Figure 3. The two active-site aspartates, Asp32 and Asp218, are indicated by asterisks.
rhizopuspepsin has just two residues enclosed, pepsin four
(between Cys45 and Cys50 using pepsin numbering),
and renin and cathepsin D six each. The result is that this
loop now forms a new boundary for the extended bind-
ing cleft of SAP2, as seen clearly in Figures 2 and 3.
Region 111
Located to the inside of the disulphide loop (47-59) is a
significant deletion centred about residue 118 which
makes an even greater impact on the shape of the binding
cleft. The absence of the 7-8 residues possessed by the
other enzymes means the loss of a small helical segment
(110-116 using pepsin numbering) that normally pro-
jects into the cleft and contributes to the S1 binding site
(to use the standard notation [36]).
Region IV
A short insertion, corresponding to residues 247-249, is
accommodated within an existing large loop, found well
away from the active centre. This is a region of consider-
able flexibility, characterised by high B factors.
Region V
A similar insertion at positions 286-290 enlarges the
adjacent loop, both loops being connected to the disul-
phide Cys256-Cys294. These two loops project out into
the solvent further than in other aspartic proteinases and
may be of antigenic significance, as may be the disulphide
loop in the N-terminal domain.
Region VI
There is a significant deletion of 4-7 residues at SAP2
position 303, corresponding to the loss of a short looped
segment that projects from the surface, markedly so in
the case of the mammalian homologues (Fig. 3). This
corresponds again to an alteration in the boundary of the
extended binding site.
Region VII
A C-terminal extension of about ten residues is nicely
stitched to the side of the N-terminal domain, residues
337-339 forming a small antiparallel [3 sheet structure
with residues 174-176. The C terminus in SAP2 is in
close proximity to the N terminus (a Cot-Cot separation
of 8.4 A) in contrast with the large separations seen in
the other aspartic proteinases. The closest approach
between the ends of the chain (4.8 A) is made by
residues 2 and 340.
Figure 4 also highlights the variability in aspartic
proteinase sequences, not just in the external residues
but also in the hydrophobic core. Conserved residues
include those at the catalytic centre, the C-terminal
domain cystine, the tyrosine in the flap, 14 glycines, and
one tryptophan. SAP2 possesses only this one
tryptophan residue (see Trp39 in Fig. 1). The active site
of SAP2 contains the contributing sequences DTGS
(32-35) and DSGT (218-221) with the serine at
position 219 being unusual amongst monomeric
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aspartic proteinase structures that are currently
deposited in the Brookhaven Protein Data Bank [35].
However this substitution does not influence the geom-
etry of the catalytic centre.
Inhibitor binding
Pepstatin is the archetypal aspartic-proteinase inhibitor
and has been studied crystallographically in complex
with rhizopuspepsin [26], cathepsin D [31,32], endoth-
iapepsin [24] and pepsin (among the monomeric aspar-
tic proteinases). It is an extended hexapeptide which is
thought to act as a tetrahedral transition-state mimic by
virtue of a central statine residue containing the non-
scissile bond -(CHOH-CH2)-. The hydroxyl group
forms hydrogen bonds with the two catalytic aspartate
side chains (Fig. 5). The insertion of these two extra
carbon atoms in the backbone results in the P'1 side
chain (alanyl) being displaced towards the S'2 pocket in
the enzyme (using standard nomenclature). Inhibitor
A70450, a renin-based inhibitor, is a pseudo-hexapep-
tide (Fig. 5) in which the peptide bond to be hydrol-
ysed is replaced by the hydroxyethylene isostere, a
common strategy in the design of aspartic proteinase
inhibitors. Other noteworthy features of A70450
include a lactam ring that severely restricts the confor-
mation around P3, the benzyl side chain of P3 having
the (R)-configuration, a piperazine substituent at P4,
and an n-butyl side chain at P2 [18]. The electron den-
sity for A70450 was well defined at 2.1 A resolution
(Fig. 6a). Although the SAP2-pepstatin complex was
determined only at medium resolution (3 A) and should
:herefore not be over-interpreted, the density for the
pepstatin molecule was quite clear (Fig. 6b) and the
final model is of good quality.
The pepstatin molecule binds in an open conformation,
with an inverse y turn between the CO and NH of the
two statine residues, similar to that observed in other
pepstatin-protein complexes. It also forms a very similar
set of hydrogen bonds to the protein (Fig. 5). The involve-
ment of active-site residues Asp32 and Gly34 of one loop
and Asp218, Gly220 and Thr222 in the other, together
with flap residues Gly85 and Asp86, is a common theme as
these residues are highly conserved, especially amongst the
fungal members. Where differences exist in the
mammalian enzymes (serine for Thr222, serine or threo-
nine for Asp86) corresponding hydrogen bonds are still
nade. Outside these eleven 'core' hydrogen bonds there
are many van der Waals contacts, involving the residues
isted in Table 1. Again, most of these residues or their
equivalents, are found in the binding sites of other aspartic
proteinases. Thus, it would appear that SAP2, despite its
many differences from other related enzymes, binds pep-
statin A in a conservative way, albeit less tightly than does
Fig. 5. Hydrogen-bonding diagrams.
(a) A70450 bound to SAP2. (b) Pep-
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Fig. 6. Difference (Fo-F c) electron den-
sity for inhibitors bound to SAP2.
(a) A70450, using data between 20.0 A
and 2.1 A. (b) Pepstatin, using data
between 20.0 A and 3.0 A. The contour
level is at 3 in both cases. (Figure
drawn using O/OPLOT [34].)
Table 1. SAP2 residues in contact (<4 A) with inhibitors.
Subsite Inhibitor
A70450
S4
S3
D86, S88, S18
V12, T13, D86, S118,
G220, T221, T222
S2 Y84, G85, D86,
T221
N301, A303, 1305
S1 130, D32, G34, Y84
1119, 1123,
D218, G220, T221
S'1 G34, Y84, G85
E193, L216, D218
S'2 G34, S35, 182, Y84
N131, A133
S'3
Pepstatin
V12, T222
V12, D86
G220, T221,T222
Y84, G85, D86
G220, T221,Y225
130, D32, G34, Y84, G85
1123
D218, G220, T221
G34, S35, 182
G83, Y84
E193
rhizopuspepsin (by a factor of 19), penicillopepsin (x19),
endothiapepsin (x6) and considerably less so than pepsin
(x63) or cathepsin D (x760), according to published K
values [18,24,26,32]. There is no hydrogen bond to the
carbonyl oxygen of P4, nor to the carbonyl oxygen of the
alanine residue P'1 (P'2), as seen with cathepsin D [32]. In
comparison with endothiapepsin there are fewer stabilising
interactions to the C-terminal statine at P'2 (P'3) and to
P3 valine [24]. The number of contacts made, or not
made, because of sub-optimal filling of pockets, and the
conformational determinants of these pockets, will all
contribute to the strength of the enzyme-inhibitor inter-
action, but overall there seems to be no simple explanation
for the observed differences in binding affinity.
Inhibitor A70450, although it binds to SAP2 with a
strength around 20-fold greater than that of pepstatin,
forms two fewer hydrogen bonds (Fig. 5) due to the lac-
tam ring linking the main-chain nitrogen atoms of P3
and P2. One of the bonds formed involves a well-
ordered water molecule that is close (2.7 A) to the car-
bonyl oxygen of P3, a feature that has also been observed
in complexes with other aspartic proteinases, especially
endothiapepsin [25]. The other hydrogen bonds are
Italicised residues are those which vary among the SAP 1-6
isozymes.
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Fig. 7. Stereoview showing an overlay
of the two inhibitors A70450 (thick line)
and pepstatin (thin line) based on a
superposition of the SAP2 structures as
determined in each of the complexes.
The orientation is consistent with the
schematic representation in Figure 5.
highly conserved, with the shortest involving the interac-
tion of an oxygen from each catalytic aspartate with the
hydroxyl of the hydroxyethylene transition-state isostere.
The number of contacts <4 A from SAP2 to P'2 and to
P3 is significantly greater than seen with pepstatin.
Residue P3 possesses a side chain equivalent to that of
D-phenylalanine and this aromatic ring forms close inter-
molecular interactions with the cyclohexyl group in P1
which folds back towards P3 and P4, resulting in a clus-
tering of all four rings. The positioning of P4 and P3,
that is, three of the rings, is controlled by rotation about
the N-Cox bond of P2. As indicated in Table 1, the flap
residues Ile82, Tyr84, Gly85, Asp86 and Ser88 make
many contacts across the whole inhibitor. Indeed the
tyrosine side chain slots between the P1 cyclohexyl ring
and the n-butyl side chain at P'2.
The striking difference in conformation between A70450
and pepstatin is the curved backbone between P4 and P1
in the former, due to the lack of flexibility imposed by
the lactam ring (Fig. 7). The methylpiperazine group at
P4 is able to occupy most of the space made available by
the SAP2 helix deletion at position 118, a situation not
exploited by pepstatin with its greater flexibility. Some of
the residues present in regions unique to SAP2, outlined
in the previous section, are involved in defining the
inhibitor-binding pockets (Table 1). These include Va112
Fig. 8. Molecular surface of SAP2, with bound inhibitor A70450.
The diagram is coloured to reflect electrostatic potential: nega-
tive charges in red, positive charges in blue. The inhibitor is ori-
ented with P4 on the right and P'2 on the left. (Figure generated
by MOLVIEWER [MJ Hartshorn, University of York].)
(in the S3 subsite), Ile119 and Ile123 (S1), and Asn301
and Ala303 (S2). The last pair help stabilise the n-butyl
side chain at P2 of A70450 but do not interact with the
shorter valyl side chain in pepstatin.
Modelling the A70450 structure, when bound to SAP2,
into the renin structure results in a clash between the
methylpiperazine (P4) and renin residue Prolll of the
helical region that is absent in SAP2 (region III). For
A70450 to bind to renin in the same conformation, a
cooperative movement of this helix and the nearby disul-
phide loop (region II) is required. Similar arguments
apply to pepsin and cathepsin D.
Conclusions
The SAP2 structure displays some significant conforma-
tional as well as sequence differences from the other fam-
ily members. It is too early to say if these differences are
sufficient to allow a synthetic peptide-based inhibitor to
select between C. albicans SAP2 (the putative virulence
factor) and human host homologues such as pepsin,
cathepsin D and renin. From the two crystallographic
analyses presented here, there are some indications as to
how one might design an inhibitor with higher speci-
ficity than A70450, for SAP2. Figure 8 shows a charged
surface representation of the binding site. The topogra-
phy suggests that an extension at P4 would result in a
better fit to the hole around position 118 that is flanked
by the disulphide loop (Fig. 8, right). The proximity of
charged residues Asp86 (to the left of P4, as shown) and
Asp120 (upper right) could also be considered in any
new design. At the P'2 end there is a smaller hole that
might be exploited, but clearly the structures of more
complexes need to be analysed in order to properly assess
conserved features of the binding site of SAP2.
It is worth noting that modelling studies indicate that a
normal (flexible) peptide backbone would permit a puta-
tive inhibitor with an L-phenylalanine side chain at P3 to
bind and interact with the enzyme at this site in a similar
way to the D-phenylalanine of A70450, and still have P4
directed into the cavity.
Assuming that an inhibitor drug with the requisite
pharmacological properties could be designed, there is
still the problem of multiple isozyme expression by
C. albicans, the control of which is not fully understood
[14]. Would an inhibitor tailored to SAP2 be able to bind
as well to the other isozymes? Of the eight SAP genes
reported, one (SAP7) is probably not expressed [14] and
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one (SAP8) has not yet been fully reported in the
literature. Table 1 highlights the 12 subsite-defining
residues (out of 27) that vary amongst the SAP 1-6
isozymes. Many of the changes involve conservative sub-
stitutions, and modelling indicates that these can be
accommodated quite comfortably. Several substitutions
that might cause some conformational rearrangement
include: Ala303--Tyr (SAP3), Ala303--Asp (SAPs 4-6),
Glu193--Lys (SAP5), Ilell19-Ala (SAPs 4-6),
Gly83---Glu (SAP3), Gly83--Lys (SAPs 4-6). Overall,
SAP1 has the most similar binding cleft to SAP2 (only
two differences); SAP3, which has the highest sequence
identity (slightly greater than SAP1) with SAP2 shows a
surprising eight changes, similar to the number seen for
SAPs 4-6. SAP4 and SAP6, in fact, have identical binding
sites, as defined in Table 1. It will be of interest to com-
pare inhibitor-binding affinities for the different isozymes.
Biological implications
Candida albicans is the major fungal pathogen of
humans, causing a variety of infections, both
superficial (e.g. thrush) and systemic (that may be
life-threatening in immunocompromised individ-
uals). The increasing frequency of such infections,
as well as the emergence of resistant strains, has
prompted calls for new drug therapies. A possible
drug target is the Candida sp. secreted aspartic
proteinase (SAP) that enables the organism to use
exogenous protein as a nitrogen source and that
has long been cited as a putative virulence factor.
Although it is now clear that there is a family of at
least eight homologous SAP genes, one of these,
SAP2, seems to be the major isoform expressed
by C. albicans. Like many other aspartic pro-
teinases, the SAP2 isoenzyme is not highly spe-
cific towards substrate and is inhibited by
pepstatin, a microbial transition-state analogue.
The synthetic hexapeptide analogue A70450
(Abbott Laboratories) is a stronger inhibitor, and
the SAP2-A70450 complex can be readily crystal-
lized. Under different conditions, the complex
with pepstatin will also crystallise.
The three-dimensional structures of the two
enzyme-inhibitor complexes show similar protein
conformations which are, in general organisation,
typical for aspartic proteinases, that is, bi-lobed,
mainly sheet structures with a central groove.
But several significant differences, especially in the
region of the binding site, distinguish the SAP2
structure from structures of other aspartic pro-
teinases. These changes include sequence inser-
tions and deletions as well as sequence changes.
Whereas pepstatin binds in an extended confor-
mation, A70450, by virtue of a lactam ring and an
(R)-benzyl configuration at P3 (using standard
notation), allows the P4 methylpiperazine to
'hook' into a pocket made by a sequence deletion.
Model building suggests that other SAP isozymes
have similar binding sites. With the knowledge
gained from these crystallographic analyses, an
opportunity exists to design an inhibitor tailored
to recognise the SAP isoenzymes in preference to
host aspartic proteinases.
Materials and methods
SAP2-A70450 complex
The SAP2 isozyme from C. albicans (Strain ATCC 10261) was
purified, and crystallized in the presence of the inhibitor
A70450 (Abbott Laboratories) [18]. The crystals belong to the
space group P43212 (see below) with unit cell dimensions
a=b=76.2 A, c=126.1 A, and one molecule in the asymmetric
unit. The successful isomorphous derivative was prepared by
soaking crystals of the complex in mother liquor containing
0.5 mM uranyl acetate for 24 h. Cell dimensions changed
slightly as a result (a=75.7 A, c=124.5 A). Diffraction data
were collected at room temperature using a Rigaku R-Axis
IIC image plate detector in conjunction with a Rigaku RU-
200HB rotating anode source, and processed using MOSFLM
(AGW Leslie, LMB, Cambridge) and programs from the
CCP4 suite [37]. Data to 2.05 A and 2.45 A resolution,
respectively, were obtained for native and derivative crystals
(see Table 2).
The structure was solved by a combination of single isomor-
phous replacement with anomalous scattering (SIRAS), and
molecular replacement (MR). A high occupancy uranyl site
was found by inspection of both the isomorphous and anom-
alous difference Patterson maps; three minor sites were located
using VECSUM within the CCP4 package. The SIRAS phas-
ing was based on these four uranyl sites, which were refined
using the program MLPHARE (CCP4 package), then
improved by solvent flattening and histogram matching using
SQUASH [38,39]. It was noted that the solvent boundary was
clearer when the phases were calculated for P43212, as com-
pared with P4 1212. The final overall figure of merit for data in
the range 20-2.5 A was 0.58. Although the SIRAS/SQUASH
phased electron density map looked promising, with elements
of [3 sheet structure clearly visible, it was difficult to relate it to
the known sequence of SAP2 due to discontinuities in the
main chain. Eight other derivatives were screened in the hope
of providing better phases but were not found to be useful.
Molecular replacement computations were performed using
AMoRE [40] from the CCP4 implementation. Various struc-
tures of aspartic proteinases bound to inhibitors are available,
and three of these were tried as search units: rhizopuspepsin
(Brookhaven entry code 3APR), endothiapepsin (5ER2) and
chymosin (4CMS). In addition, an homology model of SAP2
was constructed [17]. All four search models were aligned for
ease of comparison. Rotation function solutions were not
encouraging, with correlation coefficients all less than 10.0, and
there was little consistency between searches done at different
resolutions and between different models. However a system-
atic search for a translation function solution in both P41212
and P43212 was carried out using the top 40 rotation function
solutions for each model. One solution (ninth highest peak)
using the rhizopuspepsin model with 30-4 A data in space
group P4 3212 gave an obviously 'best' solution with the high-
est correlation coefficient (23.3) and the lowest R factor
(53.4%). These improved with rigid body fitting to a correla-
tion coefficient of 26.7 and an R-factor of 52.0%. It is worth
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noting that the correct rotation function solution was actually
present in each set of the top 40 peaks.
The MR solution clearly matched the electron density of the
2.5 A SIRAS/SQUASH phased map. Using the O program
[34] the appropriate sequence changes were made and some
reasonably straightforward rebuilding carried out. Partial
model and experimental phases were combined using
SIGMAA [42]. Some of the loop regions (47-63, 240-250,
280-290) were very poorly defined and initial refinement
using the simulated annealing procedure in X-PLOR [43] did
not reduce the R factor below 0.35 with Rfree [44] above
0.50. Further rounds of model building into combined phase
maps and restrained least squares refinement using PROLSQ
[45] gradually improved the model, a breakthrough being the
realisation that there was an out-of-register error involving
the N-terminal region. When the R factor had dropped to
0.30, model-building continued using 2Fo-F c maps with vari-
ous ill-defined segments omitted, and most of the loop
regions could then begin to be filled in. A difference map
(Fo-Fc) clearly showed the density for the inhibitor, which
was now included in the refinement (R=0.24 for all data
between 8 A and 2.1 A). Water molecules were also located
from difference maps and included if their density was above
3o and if their positions were chemically sensible. The final
model included all 342 residues (2560 non-hydrogen atoms),
the inhibitor (53 atoms) and 120 water molecules, giving an
R factor of 0.195 (Rfree=0.268) for all data in the range
8.0-2.1A (21780 reflections). The rms deviations from ideal-
ity (as per PROLSQ) are 0.013 A (bond lengths), 0.032 A
(angle distances) and 0.033 A (planarity). The average B value
for protein atoms was 35 A2, consistent with the overall B
estimated from a Wilson Plot [461, whereas for the inhibitor
atoms the value was 27 A2 . Several parts of the model are
poorly defined with electron density less than lor in 2Fo-F c
maps, and with high B values. These are residues 246-249
and 283-287, both segments being contained in large loops
within the C domain and also the side chain of Lys271.
SAP2-pepstatin complex
Orthorhombic crystals were grown by the hanging drop
method from 0.1 M sodium cacodylate pH 6.5, 0.1 M zinc
acetate, 16% PEG 8000. The space group was P2 2121 with
unit cell dimensions a=49.2 A, b=67.1 A, c=98.6 A, and one
molecule per asymmetric unit. Data collection and processing
was as above except that DENZO [47] was used for indexing
and integration of images. The crystals did not diffract much
beyond 3 A. Using the SAP2 coordinates, derived from the
SAP2-A70450 structure as search unit, a molecular replace-
ment solution using AMoRE was readily obtained. The high-
est peak in the rotation function was 9 times the rms deviation
from the mean and more than twice the next peak, with a cor-
relation coefficient of 25.3. When applied to the translation
function a clear solution was obtained (correlation 58.7, R fac-
tor 0.42 which improved to 64.4 and 0.38 respectively after
rigid-body refinement). Alternating model building (using O)
into 2Fo-Fc OMIT maps with rounds of restrained least-
squares refinement (PROLSQ) quickly reduced the R-factor.
A difference map, calculated when the R factor was 0.23,
revealed unambiguous density for the pepstatin molecule (47
atoms). Given the high ratio of parameters to data, B values
were held constant at 30 A2 for most of the molecule and
50 A2 for the middle regions of the three largest loops. The
final R factor was 0.196 for 8-3 A data. No water molecules
were included. Deviations from stereochemical ideality were
0.019 A (bonds) and 0.046 A (angle distances).
The coordinates of the SAP2-A70450 complex are being
deposited with the Brookhaven Protein Data Bank.
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Note added in proof
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